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Abstract
Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a major antiapoptotic protein 
and an important cytokine and chemotherapy resistance factor that suppresses cytokine- and chemotherapy-
induced apoptosis. c-FLIP is expressed as long (c-FLIPL), short (c-FLIPS), and c-FLIPR splice variants in human 
cells. c-FLIP binds to FADD and/or caspase-8 or -10 and TRAIL receptor 5 (DR5). This interaction in turn prevents 
Death-Inducing Signaling Complex (DISC) formation and subsequent activation of the caspase cascade. c-FLIPL 
and c-FLIPS are also known to have multifunctional roles in various signaling pathways, as well as activating and/
or upregulating several cytoprotective and pro-survival signaling proteins including Akt, ERK, and NF-κB. In addition 
to its role in apoptosis, c-FLIP is involved in programmed necroptosis (necrosis) and autophagy. Necroptosis is 
regulated by the Ripoptosome, which is a signaling intracellular cell death platform complex. The Ripoptosome 
contains receptor-interacting protein-1/Receptor-Interacting Protein-3 (RIP1), caspase-8, caspase-10, FADD, and 
c-FLIP isoforms involved in switching apoptotic and necroptotic cell death. c-FLIP regulates the Ripoptosome; in 
addition to its role in apoptosis, it is therefore also involved in necrosis. c-FLIPL attenuates autophagy by direct 
acting on the autophagy machinery by competing with Atg3 binding to LC3, thereby decreasing LC3 processing and 
inhibiting autophagosome formation. Upregulation of c-FLIP has been found in various tumor types, and its silencing 
has been shown to restore apoptosis triggered by cytokines and various chemotherapeutic agents. Hence, c-FLIP is 
an important target for cancer therapy. This review focuses on (1) the anti-apoptotic role of c-FLIP splice variants in 
preventing apoptosis and inducing cytokine and chemotherapy drug resistance, as well as its roles in necrosis and 
autophagy, and (2) modulation of c-FLIP expression as a means to enhance apoptosis and modulate necrosis and 
autophagy in cancer cells.
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Introduction
Various cell death signaling pathways have been described that are 
regulated at several levels. While the mitochondrion is the initiation 
point of these signals [1,2], there are several types of signaling 
platforms in cells that can initiate cell death. These complexes include 
the death-inducing signaling complex (DISC) [3], TNF complex 
II [4], apoptosome [5], PIDDosome [6], and Ripoptosome [7,8]. 
Interestingly, the c-FLIP isoforms, c-FLIPL, c-FLIPS, and c-FLIPR, 
regulate apoptosis [by interacting with the death signaling complex 
downstream of TNF-α receptors, Fas, and TRAIL receptors 1 (DR4) 
and 2 (DR5), necroptosis, and autophagy]. In this review, I discuss (1) 
apoptosis signaling pathways and the role of c-FLIP isoforms as critical 
anti-apoptotic and drug resistance factors, (2) the roles of c-FLIP 
isoforms in regulating necrosis and autophagy, and (3) the potential for 
improving the outcome of cancer therapy by targeting c-FLIP isoforms.
Apoptosis Signaling Pathways
Two main signaling pathways, the intrinsic or mitochondrion-
initiated pathway and the extrinsic or cell surface death receptors 
pathway, regulate apoptosis (Figure 1) [1,2,9,10]. In the intrinsic 
pathway, cytochrome c, apoptosis-inducing factors including Smac/
DIABLO, HtrA2/Omi, and Endonuclease G (endoG) are released from 
the mitochondrial to the cytosol [11,12]. Upon release, cytochrome c 
and dATP bind to apoptotic proteinase-activating factor-1 (Apaf-1), 
and this complex along with adenine nucleotides form the apoptosome 
and promote procaspase-9 autoactivation [12,13,14]. Apoptosome 
assembly is a crucially important point in the mitochondrial pathway 
of apoptosis, consisting of a wheel-like heptamer of seven Apaf-1 
molecules and seven cytochrome c molecules that bind and activate 
the initiator caspase-9, which in turn activates caspases-2, -3, -6, -7, -8, 
and -10 [13,14]. Apoptosis induced by different death stimuli requires 
direct activation of Bax and BAK at the mitochondria by a member of 
the Bcl-2 homology domain-3 (BH3)-only family of proteins including 
Bid, Bim, or PUMA [15]. The various anti- and pro-apoptotic members 
of the Bcl-2 family form an interactive network that finally regulates 
the release of apoptosis triggering factors such as cytochrome c to the 
cytoplasm [16]. This release of cytochrome c is associated with opening 
the Permeability Transition Pore (PTP) and a collapse of mitochondrial 
transmembrane potential (Δψm) due to the intake of Ca2+ following 
its release into the cytosol from the Endoplasmic Reticulum (ER) [9, 
17]. In the death receptor-mediated or extrinsic apoptosis pathway 
(e.g., Fas/Fas ligand interaction, tumor necrosis factor α [(TNF-α)/
TNF receptor 1 (TNFR1), or TRAIL/DR5 interaction and cell death], 
the initiator caspases-8 and -10 activate the downstream caspases 
including caspases-3, -6, and -7 [10,18,19]. Active caspases-8 and -10 
are known to cleave a pro-apoptotic Bcl-2 family member, Bid, and 
the truncated Bid induces mitochondrial cytochrome c release [19-23], 
thereby linking the two pathways. After activation, both caspases-8 and 
-9 activate caspase-3, which in turn cleaves other caspases and many 
cellular proteins [24-26]. Scaffidi et al. [27,28] also have identified two 
different CD95 apoptosis signaling cell types, type I and type II. In 
type I cells, CD95-mediated apoptosis is initiated by large amounts of 
active caspase-8 formed at the DISC and subsequent direct cleavage of 
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caspase-3. In contrast, in type II cells, very little DISC formation and 
small amounts of active caspase-8 sufficient to trigger the mitochondrial 
apoptosis pathway lead to a significant activation of both caspase-8 and 
caspase-3. Overexpressed Bcl-2 or BclxL only can block apoptosis in 
type II cells [28]. These authors [28] have shown that several apoptosis-
inhibiting or -inducing stimuli only affect apoptosis in type II cells. 
Interestingly, since c-FLIP acts directly at the DISC, it blocks CD95-
mediated apoptosis in both type I and type II cells [28].
Cellular FLICE-like Inhibitory Protein (c-FLIP)
Viral FLICE-Inhibitory Proteins (v-FLIPs) were first identified 
by a bioinformatic search for a novel death effector domain (DED-
containing virus-encoded apoptotic regulatory proteins) by Thome 
et al. [29]. These authors described six v-FLIPs and showed that cells 
expressing v-FLIPs were resistance to Fas (CD95/APO-1)- ,TRAILR1-, 
and TNFR1-Induced Apoptosis [29,30]. v-FLIPs contain two DEDs, 
bind to the DED of FADD and interfere with the FADD-procaspase 
8 interaction, leading to suppressed recruitment of procaspase-8 to 
the DISC and its activation [29]. Shortly after the characterization of 
v-FLIPs, the mammalian cellular homologue was identified and termed 
c-FLIP [31]. c-FLIP is also known as Casper, iFLICE, FLAME-1, CASH, 
CLARP, MRIT, or usurpin [32]. c-FLIP consists of 13 distinct spliced 
variants, three of which are expressed as proteins: the 26 kDa short 
form (c-FLIPS), the 24 kDa form of c-FLIP (c-FLIPR), and the 55 kDa 
long form (c-FLIPL) [33-37] (Figure 2). The three c-FLIP variants can 
interact with the adaptor protein FADD. The structures of c-FLIPS and 
the viral FLIP (v-FLIP) proteins are similar, except that the two DEDs 
of c-FLIPS are followed by 20 amino acids that appear to be crucial for 
its ubiquitination and targeting for proteasomal degradation [32,34-
36]. c-FLIPR also contains two DEDs but lacks the additional carboxy 
(C)-terminal amino acids that are present in c-FLIPS. The C-terminus 
of c-FLIPL is longer than that of c-FLIPS and closely resembles the 
structure of caspases-8 and -10 [32,34-36], but this region of c-FLIPL 
does not contain a functional caspase domain. This lack of caspase 
activity is the result of several amino acid substitutions, particularly the 
crucial cysteine residue in the catalytic domain which is necessary for 
the catalytic activity of caspases [32,34]. Additionally, c-FLIPL has a 
caspase-8 cleavage site at position Asp-376 (LEVD); c-FLIPL cleavage 
at this site produces the proteolytic fragment variant p43c-FLIP 
[18,19]. The C-terminal region of c-FLIPS and c-FLIPR play a crucial 
role in ubiquitination and degradation as well as the anti-apoptotic 
function of these isoforms [18,19,36]. In humans, a single nucleotide 
polymorphism in a 3’ splice site of the c-FLIP gene determines 
whether c-FLIPS or c-FLIPR is made [37]. An intact splice site directs 
production of c-FLIPS, but the splice-dead variant causes production 
of c-FLIPR [37].
c-FLIP Function 
c-FLIP isoforms are Death Effector Domain (DED)-containing 
proteins that are recruited to the DISC and regulate activation of 
caspases-8 and -10 in the death receptor signaling pathways (Figure 
1). While the functional roles of c-FLIPL and c-FLIPS in apoptosis 
are well documented, their differential roles in cancer are not well 
established. Moreover, the function of c-FLIPR in cancer is poorly 
understood. Recent results demonstrated that expression of c-FLIPR 
in hematopoietic cells supports an efficient immune response against 
bacterial infections [37]. In humans a 3’ splice site of the c-FLIP gene 
(rs10190751A/G) determines whether either c-FLIPS or c-FLIPR is 
produced [38].
Regulation of c-FLIP Expression
It is well established that c-FLIP is regulated both at the 
transcriptional and posttranscriptional levels by various stimuli [34,38]. 
A diverse group of transcription factors are known to transcriptionally 
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Figure 1: Apoptosis signaling pathways and roles of c-FLIP in preventing apoptosis. Interaction of TRAIL with its receptors DR4 and DR5 or binding of Fas ligand to 
Fas receptor initiates the death receptor (extrinsic) and subsequently mitochondrial apoptosis signaling pathways through FADD-dependent autocatalytic activation 
of caspases-8 and -10 and Bid cleavage to truncated Bid. c-FLIP isoforms suppress caspase-8 and -10 activation, therefore preventing the downstream apoptosis 
cascade.
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regulate the c-FLIP gene [19,34,36,39-47]. The expression of c-FLIP is 
regulated at the transcriptional, translational, and post-translational 
levels [19,34,36]. The transcriptional control of c-FLIP isoforms is 
quite complex and differentially regulated in various cells in a signal-
specific manner. While numerous transcription factors trigger c-FLIP 
transcription including NF-κB, AP-1 (cFos/c-Jun), P53, FoxO, CREB, 
NFATc2, EGR1, AR, SP1 [19,34,36,39-43], and p63 (NP63) [40], others 
induce repression of c-FLIP expression such as c-Fos, c-myc, FoxO3a, 
IRF5, and SP3 [44-47]. E2F1 transcription factor also downregulates 
c-FLIPS in lung adenocarcinoma [48]. Moreover, in the presence of 
androgens prostate apoptosis response factor-4 (Par-4) is recruited to 
the c-FLIP promoter and enhances c-FLIP expression in prostate cancer 
cells [41]. Viral proteins are capable of targeting cellular signaling 
pathways that regulate cellular non-specific immune responses and 
cell death. In this regard, Halder et al. [49] recently demonstrated 
that influenza A virus matrix protein 1 (M1) activates RelB (an NF-κB 
member)-mediated survival genes (c-FLIP, cIAP1, and cIAP2).
Post-Transcriptional Regulation of cFLIP Expression
c-FLIPS can also be upregulated at the translational level and 
cause TRAIL resistance in glioblastoma multiforme (GBM) cells due 
to activation of the Akt mammalian target of rapamycin (mTOR)-p70 
S6 kinase 1 (S6K1) pathway [50,51]. Conversely, inhibition of mTOR 
or its target S6K1 suppressed polyribosomal accumulation of c-FLIPS 
mRNA, c-FLIPS protein expression, and promoted TRAIL resistance 
in GBM cells. Moreover, it has been shown that Rocaglamide (Roc) 
sensitizes resistant adult Tcell leukemia/lymphoma (ATL) cells to 
DR4- and DR5-mediated apoptosis by translational suppression 
of c-FLIPS through inactivation of the translation initiation factor 
4E (eIF4E) [52]. c-FLIP variants are short-lived proteins that are 
predominately degraded by the ubiquitin-proteasome degradation 
system. Both c-FLIP isoforms can be degraded by the proteasome. 
However, c-FLIPS is particularly sensitive to ubiquitination and 
proteasomal degradation, partly due to two crucial lysine residues in 
the C-terminal 20 amino acids that are unique to c-FLIPS [53]. c-FLIPL 
and c-FLIPS levels are also regulated by JNK activation via the E3 
ubiquitin ligase Itch [54]. Phosphorylation events also play important 
roles in regulating c-FLIP protein levels. For instance, protein kinase 
C phosphorylation at the serine 193 (S193) residue of c-FLIPS inhibits 
its polyubiquitination, stabilizes c-FLIPS levels, and increases cell 
survival [55]. S193 phosphorylation is markedly increased by treatment 
with the PKC activator 12-Otetradecanoylphorbol-13-acetate and 
decreased by inhibition of PKCα and PKCβ. Phosphorylation of the 
S193 residue also decreased the ubiquitination of c-FLIPL but did 
not affect its stability, indicating that S193 phosphorylation has a 
different function in c-FLIPL than in c-FLIPS. Kerr et al. [56] reported 
a novel interaction between c-FLIP and the DNA repair protein Ku70 
and showed that Ku70 regulates FLIP protein stability by inhibiting 
its polyubiquitination. Moreover, these authors demonstrated that 
HDAC6 is a critical regulator of Ku70 acetylation and c-FLIP protein 
stability [57,58]. Reactive Oxygen Species (ROS) have been implicated 
in the degradation of c-FLIP protein [38,39]. Recently, Wilkie-
Grantham et al. [59] uncovered the mechanism by which ROS post-
transcriptionally regulate c-FLIP protein levels in prostate cancer cells. 
They also identified threonine 166 as a novel phosphorylation site and 
showed that Thr-166 phosphorylation is required for ROS-induced 
Lys-167 ubiquitination. These authors identified lysine 167 as a novel 
ubiquitination amino acid of c-FLIPL which is important for ROS-
dependent degradation and regulates both the stability of c-FLIP and 
the sensitivity of cancer cells to TRAIL.
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Figure 2: Structures of c-FLIP variants and cleavage products. c-FLIP isoforms (c-FLIPL, c-FLIPS, and c-FLIPR) contain two death effector domains (DED1 and DED2) 
at their N termini which are required for DISC recruitment. In addition to two DEDs, c-FLIPL has a significant similarity to caspase-8 and has a large (p20) and a small 
(p12) caspase-like domain which are catalytically inactive. c-FLIPS and c-FLIPR consist of two DEDs and a small C terminus. c-FLIPL can be cleaved by caspase-8 
generating the N-terminal fragment p43-FLIP or p22-FLIP. The phosphorylation (P) sites and ubiquitination (U) sites are indicated [35,37,60]. The p20/p12 regions 
interact with TRAF2 and RIP1, respectively, and Ku70 binds to DED2 [57].
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c-FLIP inhibits apoptosis
c-FLIP is involved in TRAIL, Fas, TNF-α, and chemotherapeutic 
drug resistance in a wide range of human malignancies [19,32,34-
36]. Moreover, many studies encompassing diverse types of human 
cancer cells have revealed that the role of c-FLIP in cancer cells is anti-
apoptotic. Furthermore, interference with c-FLIP expression sensitizes 
tumor cells to death ligands and chemotherapy in experimental models 
[10,25]. In addition to its function as an apoptosis modulator, c-FLIP 
exerts other cellular functions including increased cell proliferation 
and tumorigenesis [19,34-36].
The structural differences between human c-FLIP variants indicate 
distinct regulatory roles for c-FLIPL and c-FLIPS in apoptosis. All three 
c-FLIP isoforms have two DED domains and can bind to the DISC. 
c-FLIPS and c-FLIPR block procaspase-8 activation and apoptosis 
[18,19,60-62]. In a similar way to c-FLIPS, c-FLIPL acts as an anti-
apoptotic molecule when it is present at high concentrations at the DISC 
[18,63]. c-FLIPL can also act as a pro-apoptotic molecule under strong 
death receptor stimulation, or in the presence of high levels of c-FLIPS 
or c-FLIPR which promotes the activation of procaspase-8 at the DISC 
[11,18,63]. We have previously demonstrated that c-FLIPL or c-FLIPS 
prevents caspase-8 and -10 activation [64]. We also have demonstrated 
that c-FLIPL interacts with DR5, FADD, and caspase-8 forming an 
Apoptotic Inhibitory Complex (AIC) in MCF-7 breast cancer cells 
[45]. Moreover, silencing the c-FLIP gene by a specific siRNA leads 
to death ligand-independent but DR5-, FADD-, and caspase-8- and 
-9-dependent apoptosis in these cells, and the knockdown of c-FLIP 
expression inhibits breast cancer cell proliferation and triggers 
spontaneous apoptosis by activating both the death receptor and 
mitochondrial pathways [64]. Jin et al. [65] have demonstrated that the 
peptide corresponding to the DR5 binding domain of c-FLIPL induces 
apoptosis in cancer cells. It is possible that inhibiting the interaction 
of DR5 and c-FLIPL by peptides or small molecule inhibitors could 
provide a mechanism by which tumor-selective apoptosis can be 
achieved. The dynamic interaction between procaspase-8 and c-FLIP 
isoforms at the DISC and regulation of apoptosis have been thoroughly 
reviewed [18,32,36,66].
Upregulation of c-FLIP in Human Cancers
c-FLIP has been found to be overexpressed in several types of 
malignancies and could be associated with cancer progression due to 
its ability to inhibit the apoptotic process. Elevated expression levels 
of c-FLIP have been reported in colorectal cancer [67,68], bladder 
urothelial cancer [69], cervical cancer [70], Burkitt’s lymphoma [71], 
non-Hodgkin’s lymphoma [72], Head and Neck Squamous Cell 
Carcinoma (HNSCC) [73], hepatocellular cancers [74], and high-grade 
prostatic intraepithelial neoplasia (HGPIN) with maximal c-FLIP 
expression detected in Castrate-Resistant Prostate Cancer (CRPC) 
[75]. c-FLIP upregulation is also seen in gastric cancer and plays an 
important role in lymph node metastasis, which ultimately contributes 
to tumor progression [76]. c-FLIP variants are also expressed in 
pancreatic intraepithelial neoplasms as well as pancreatic ductal 
adenocarcinomas, while c-FLIP was not detected in normal pancreatic 
ducts [77]. While the epithelium of the normal cervix and low-grade 
squamous intraepithelial lesions were mainly negative for c-FLIP, high-
grade intraepithelial lesions as well as cancer samples showed increased 
c-FLIP expression [78]. This finding suggests that c-FLIP expression 
may serve as a potential cervical cancer progression marker. Recent 
results demonstrated that c-FLIP may play an important role in the 
potential of osteosarcoma to metastasize to the lung [79]. McLornan 
et al. [80] have provided evidence that c-FLIP may also serve as a 
prognostic biomarker in Acute Myeloid Leukaemia (AML). While 
overexpression of the c-FLIPS variant has been reported in human lung 
adenocarcinomas with low levels of E2F1, c-FLIPL protein expression 
was not altered [48]. Moreover, Ueffing et al. [39] demonstrated that an 
increased lymphoma risk is associated with the rs10190751 A genotype 
causing c-FLIPR expression.
Roles of c-FLIP in Necroptosis and Autophagy
In addition to its role in apoptosis, c-FLIPL also plays an 
important role in necroptotic cell death [7,8] and autophagy [81-83]. 
Moreover, vFLIP also plays a major role in autophagy [81,84-86]. 
Recent results have demonstrated that necroptosis is a programmed 
receptor-interacting protein 1/receptor-interacting protein-3 (RIP-
1/RIP-3)-dependent necrotic cell death induced when caspase-8 
activation is inhibited [88]. Previous reports have shown that c-FLIPL 
regulates necroptosis through the formation of the signaling platform 
Ripoptosome, a RIP1/caspase-8-containing intracellular cell death 
complex [7,8]. Moreover, the cellular inhibitor of apoptosis proteins 
(cIAPs) block Ripotosome formation. While c-FLIPL prevents 
Ripoptosome formation, interestingly, c-FLIPS promotes its assembly 
(Figure 3). Therefore, c-FLIP isoforms in the Ripoptosome determine 
whether cell death occurs by RIP3-dependent necroptosis or caspase-
dependent apoptosis [8]. 
Autophagy is a degradation pathway by which cytoplasmic 
components including various damaged cytoplasmic organelles and 
unused long-lived proteins are sequestered in the autophagosomes, 
which are delivered to the lysosome to form an autolysosome for final 
degradation (Figure 4). Autophagy as a programmed cell survival 
mechanism is important in regulating and maintaining several 
normal human physiological processes [88-90]. Autophagy also is 
implicated in the pathogenesis of several diseases in human including 
cancer, neurodegenerative diseases, aging, muscle diseases, infection, 
and immunological diseases [90-96]. While autophagy can suppress 
tumor growth, it also enables tumor cells to survive under stress [97]. 
Suppression of autophagy can also sensitize cancer cells to anticancer 
therapy [99,100], but under the apoptosis deficiency condition, 
autophagy can also cause cell death termed “autophagic cell death” 
[95,100,94].
The autophagy pathway is controlled by complex molecular 
machinery [101,102]. Beclin-1, its binding partner class III 
phosphoinositide 3-kinase (PI3K) and other cofactors [103] form the 
complex termed Vps34 which is required for initiating formation of 
the autophagosome in autophagy [104,105]. During autophagosome 
formation, the microtubule-associated protein 1 Light Chain 3 
(LC3) ubiquitin-like protein is cleaved by the Atg4 cysteine protease 
which is then activated by the Atg7 E1-like enzyme and transferred 
to the Atg3 E2 enzyme. LC3 is in turn conjugated to the lipid 
phosphatidylethanolamine and embedded into the membranes 
for autophagic vesicle expansion [105-107]. Moreover, c-FLIP or 
vFLIP plays a role in autophagy [81,85,87], demonstrating that these 
proteins suppress autophagy by preventing Atg3 from binding and 
processing LC3. Therefore, FLIP expression effectively suppresses 
cell death with autophagy resulting from treatment with rapamycin, 
an effective anti-cancer drug. Lee et al. [81] also initially identified an 
autophagy pathway checkpoint by which c-FLIP and vFLIP limit the 
Atg3-mediated step of LC3 conjugation and regulate autophagosome 
biosynthesis. Moreover, these authors identified the FLIP-derived 
short peptides (a DED1 alpha2-helix ten amino acid [alpha2] peptide 
or a DED2 alpha4-helix twelve amino acid [alpha4] peptide of FLIP) 
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which individually bind to FLIP and Atg3, effectively inhibit Atg3-
FLIP interaction without affecting Atg3-LC3 interaction, and induce 
significant growth inhibition and cell death with autophagy. Similarly, 
a recent study also provides evidence that anti-FLIP peptides induce 
autophagy by inactivating the anti-autophagy activity of c-FLIP, and 
that this is associated with their antiviral effects against enterovirus 71 
(EV71) [87]. These peptides may potentially be useful as anticancer 
therapies. 
c-FLIP Activates Cytoprotective and Proliferation 
Pathways
c-FLIP activates several cytoprotective signaling pathways 
involved in regulating cell survival, proliferation, and carcinogenesis. 
Overexpression of c-FLIPL activates NF-κB and ERK signaling by 
binding to adaptor proteins in each pathway, such as TNFR-associated 
factors 1 (TRAF1) and 2 (TRAF2), Receptor-Interacting Protein 1 (RIP), 
and Raf-1 [108-110] (Figure 3). The caspase-8 processed N-terminal 
fragment of c-FLIPL (p43cFLIP) is more efficient than c-FLIPL at 
recruiting TRAF2 and RIP1, leading to more robust NF-κB activation 
[110,111]. In non-apoptotic cells, c-FLIP and the procaspase-8 
heterodimer and result in a NH2-terminal fragment of c-FLIP (p20-
FLIP) which is the key mediator of NF-κB activation by binding to 
the IKK complex [112]. c-FLIP may also provide the molecular switch 
from Fas-triggered apoptosis to Fas-promoting cell proliferation [113]. 
Recently, Golan-Gerst et al. [114] demonstrated that c-FLIP silencing 
inhibited Fas-induced proliferation of fibrotic lung myofibroblasts 
and made them susceptible to Fas-induced apoptosis. Piao et al. [115] 
recently demonstrated that c-FLIP expression controls the homeostasis 
of Intestinal Epithelial Cells (IEC) and hepatocytes by preventing cell 
death induced by TNF-α, FasL, and TRAIL. The mammalian target of 
rapamycin (mTOR) is known to positively regulate cell proliferation 
and survival through the formation of complexes with raptor (mTOR 
complex 1; mTORC1) or rictor (mTOR complex 2; mTORC2). Recent 
results revealed that mTORC2 stabilizes c-FLIPS, hence this cell 
proliferation/survival signaling complex regulates death receptor-
mediated apoptosis [116]. Recently, Jing et al. [117] demonstrated 
that the H204 residue of c-FLIPL binds to calmodulin (CaM) and a 
point mutation at this amino acid was found to markedly reduce CaM 
binding, which mediates the anti-apoptotic function of c-FLIPL in 
cholangiocarcinoma cells. Further characterizing the CaM/c-FLIP 
interaction may provide a new therapeutic target for developing 
anticancer therapies [117]. By co-immunoprecipitation experiments, 
Quintavalle et al. [118] demonstrated that the interaction between 
Akt and c-FLIPL enhances the anti-apoptotic functions of Akt by 
modulating Gsk3-β activity. Moreover, these authors have shown 
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mitochondrial and death receptor pathways. c-FLIPL inhibits. FLIP isoforms. Its formation is independent of the mitochondrial and death receptor pathways. C-FLIPL 
inhibits Ripoptosome formation [7, 8], while c-FLIPS promotes Ripoptosome assembly [8]. IAPs inhibit Ripoptosome-mediated apoptosis and necrosis [7,8].
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Figure 4: c-FLIPL mediates regulation of autophagy. Upon cellular stress, autophagosome formation can be induced. c-FLIPL attenuates autophagy by directly acting 
on the autophagy machinery by inhibiting Atg3 binding to LC3, thereby decreasing LC3 processing.
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that c-FLIPL overexpression interferes with Gsk3-β phosphorylation 
levels and induces resistance to TRAIL in cancer cells. DNA-PK/Akt 
pathway is also reported to play a role in expression of c-FLIP [119]. 
Moreover, siRNA-mediated suppression of DNA-PK or treatment 
with 4,5-dimethoxy-2-nitrobenzaldehyde (DMNB), an inhibitor 
of DNA-PK, led to decreased phosphorylation of Akt and Bad (a 
target molecule of Akt), increased expression of DR4/DR5, and 
downregulation of c-FLIP [88]. Furthermore, c-FLIPL directly interacts 
with a JNK activator, MAP kinase kinase 7 (MKK7), in a TNFα-
dependent manner and inhibits the interactions of MKK7 with MAP/
ERK kinase kinase 1 (MEKK1), apoptosis signal-regulating kinase 1, 
(ASK1) and TGF-β-activated kinase 1. This interaction of c-FLIPL with 
MKK7 might selectively suppress JNK activation [120]. c-FLIP may 
also regulate several potentially harmful signaling pathways including 
the production of inflammatory cytokines, tumor cell migration and 
metastasis, and the activation of transcription factors critical during 
tumorigenesis [121-123]. c-FLIP overexpression can alter cell cycle 
progression and enhance cell proliferation and carcinogenesis [117]. 
Increased expression of c-FLIPL inhibited the ubiquitination and 
proteasomal degradation of β-catenin, resulting in increased cyclin D1, 
colony formation, and invasive activity in prostate cancer cells. The 
c-FLIP/β-catenin/cyclin D1 signals contributing to colony formation 
and invasion were reversed by selectively silencing c-FLIP expression 
[93]. Similarly, c-FLIP, in cooperation with FADD, enhances canonical 
Wnt signaling by inhibiting proteasomal degradation of β-catenin 
[123]. c-FLIP overexpression is also significantly related to the 
presence of high-risk human papillomavirus (HR-HPV) infection 
during the progression of cervical squamous cell cancer, and c-FLIP 
is an early marker of cervical carcinogenesis [124]. Moreover, HPV16 
E2 protein interacts with abrogates the apoptosis inhibitory function 
of c-FLIP and renders cervical cancer cell lines hypersensitive to Fas/
FasL apoptosis [71].
c-FLIP and Cancer Treatment
The roles of c-FLIP isoforms as proteins that cause resistance to 
pro-cell death signals, cytokines, and anticancer drugs have been 
established [33]. Moreover, small interfering RNAs (siRNAs) that 
specifically silence the expression of c-FLIPL in diverse human 
cancer cell lines have been shown to enhance TRAIL-induced DISC 
recruitment and increase the efficacy of chemotherapeutic agents, 
thereby elevating apoptosis. Furthermore, small molecules causing 
degradation of c-FLIP as well as decreasing mRNA and protein levels 
of c-FLIPL and c-FLIPS splice variants have been found, and much 
effort is focused on developing other c-FLIP-targeted cancer therapies. 
c-FLIP therapeutic intervention aimed at inhibiting its transcription 
and posttranscriptional changes is critical for developing anticancer 
agents [20,34]. Because of significant resemblance to caspase-8 (Figure 
2), c-FLIP protein is a very difficult target for drugs that inhibit its 
function, since small molecules capable of blocking its recruitment 
to the DISC would also likely inhibit recruitment of caspase-8 to this 
complex, thereby inhibiting apoptosis. Therefore, to reduce or inhibit 
c-FLIP expression, small molecules which target c-FLIP without 
inhibiting caspases-8 and -10 are needed. Diverse classes of agents 
that decrease c-FLIP expression and sensitize cancer cells to TRAIL 
or anticancer drugs have been reviewed [19,34,125]. These include 
some conventional anticancer drugs including cisplatin, doxorubicin, 
actinomycin D, cycloheximide, camptothecin, 9-NC, and topotecan; 
histone deacetylase (HDAC) inhibitors; the inhibitors of MEK1/2, 
PKC and PI3K, and numerous other compounds [19,34,80,125]. These 
agents affect c-FLIP transcription, trigger c-FLIP degradation through 
the ubiquitin-proteasome system, or decrease c-FLIP translation. 
Moreover, DNA damaging agents are promising drugs with regard to 
downregulating levels of c-FLIP variants [77-126,127]. Downregulating 
c-FLIP variants by small molecule therapeutics may be a potential 
strategy for developing agents to treat diseases in which this protein 
plays a role in preventing apoptosis, necroptosis, and autophagy. 
However, downregulation of c-FLIP in various cell types has induced 
significant cell death in healthy cells.
Conclusions
c-FLIP is involved in inhibiting apoptosis, programmed necroptosis 
(necrosis) and autophagy. c-FLIP variants induce resistance to death 
receptor ligands and chemotherapeutic agents in various cancer 
cells. Moreover, c-FLIP upregulation has been correlated with a poor 
clinical outcome. Therefore, c-FLIP isoforms may serve as targets 
for counteracting therapy-resistant human malignancies. Hence, 
c-FLIP may be a clinically relevant biomarker and a molecular target 
for developing therapeutics for various diseases. Various classes of 
agents can downregulate c-FLIP expression. To reduce or inhibit 
c-FLIP expression, small molecules which target c-FLIP without 
inhibiting caspases-8 and -10 are needed. Compounds that inhibit 
or downregulate c-FLIP mRNA expression or cause degradation of 
c-FLIP at the protein level through proteasome degradation will be of 
particular interest.
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